In this Q&A, Tucker explains what set Enveric apart from the first wave of psychedelic biotech companies: rather than rushing traditional molecules into the clinic, the team chose to do the harder medicinal chemistry work — designing non-hallucinogenic compounds that might deliver the therapeutic benefits of psychedelic-inspired pharmacology without the practical barriers that limit scalability.
